SCHEDULE: FMR LLC Reports 2.5% Stake in ATYR PHARMA INC

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 2,471,418 shares, representing 2.5% of ATYR PHARMA INC's common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, indicating their beneficial ownership of ATYR PHARMA INC common stock.
• As of June 30, 2026, the total number of shares beneficially owned is 2,471,418.
• This ownership represents 2.5% of the total class of securities.
• FMR LLC holds sole voting power for 2,464,141 shares and sole dispositive power for 2,471,418 shares.
• Abigail P. Johnson has sole dispositive power for 2,471,418 shares.
• The filing is an amendment to a previous filing, with the event date requiring this statement being June 30, 2026.
• Fidelity Management & Research Company LLC is identified as an Investment Adviser (IA).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes and not containing operational or financial performance updates.

Positives

• FMR LLC and Abigail P. Johnson have a significant, though not controlling, stake in ATYR PHARMA INC.
• The filing indicates a stable ownership structure from these reporting persons as of the reporting date.

Negatives

• The filing does not provide any operational or financial performance data for ATYR PHARMA INC.
• The information is limited to ownership and does not offer insights into the company's business activities or future prospects.

Risks

• The filing does not explicitly mention any risks associated with ATYR PHARMA INC.
• Potential risks for investors could stem from the lack of detailed operational information in this specific filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding ATYR PHARMA INC's future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors and investment advisors reporting significant beneficial ownership stakes. This filing indicates FMR LLC's continued investment interest in ATYR PHARMA INC, a biotechnology company.

Comparison to Industry Standards

• The ownership percentage of 2.5% by FMR LLC is a common threshold for institutional investors to report under Schedule 13G, indicating a passive investment approach rather than a controlling interest.
• Other institutional investors in the biotechnology sector often hold similar or larger stakes, but specific comparable companies and their ownership percentages are not detailed in this filing.

Related Party Transactions

• The filing notes that members of the Johnson family, including Abigail P. Johnson, are predominant owners of Series B voting common shares of FMR LLC and have entered into a shareholders' voting agreement. This agreement may lead to members of the Johnson family being deemed to form a controlling group with respect to FMR LLC under the Investment Company Act of 1940.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which can influence market perception.
• Management of ATYR PHARMA INC: Awareness of FMR LLC's ownership level is important for understanding the shareholder base.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to report any changes in their beneficial ownership of ATYR PHARMA INC's common stock as required by SEC regulations.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, FMR LLC, Abigail P. Johnson, Fidelity Management & Research Company LLC, Investment Adviser, ATYR PHARMA INC